Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to shrink lung tumors before surgery

NCT ID NCT07122687

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 32 times

Summary

This study tests whether a new drug called IBI363, when combined with chemotherapy, works better than the standard drug pembrolizumab with chemotherapy before surgery for people with a certain type of lung cancer (non-squamous, stage IB to III). About 170 adults aged 18 to 75 will be randomly assigned to one of the two treatment groups. The goal is to see if the cancer disappears completely in the removed tissue and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE IB-III NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Liaoning Cancer Hospital and Institute

    RECRUITING

    Shenyang, Liaoning, 110000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.

RESECTABLE STAGE IB-III NON-SQUAMOUS NON-SMALL CELL LUNG CANCER